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Background and Purpose  Upper respiratory infection (URI), including influenza, may ex-
acerbate the symptoms of myasthenia gravis (MG), which is an autoimmune disease that causes 
muscle weakness. There is also concern that the influenza vaccine may trigger or worsen auto-
immune diseases. The objective of this study was to determine the impacts of influenza infec-
tion and vaccination on symptom severity in MG patients.
Methods  Patients diagnosed with MG were enrolled from 10 university-affiliated hospitals be-
tween March and August 2015. Subjects completed a questionnaire at the first routine follow-up 
visit after enrolling in the study. The patient history was obtained to determine whether a URI 
had been experienced during the previous winter, if an influenza vaccination had been adminis-
tered before the previous winter, and whether their MG symptoms were exacerbated during or 
following either a URI or vaccination. Influenza-like illness (ILI) was defined and differentiated 
from the common cold as a fever of ≥38°C accompanied by a cough and/or a sore throat.
Results  Of the 258 enrolled patients [aged 54.1±15.2 years (mean±SD), 112 men, and 185 
with generalized MG], 133 (51.6%) had received an influenza vaccination and 121 (46.9%) had 
experienced a common cold (96 patients) or ILI (25 patients) during the analysis period. MG 
symptoms were aggravated in 10 (40%) patients after ILI, whereas only 2 (1.5%) experienced 
aggravation following influenza vaccination. The rate of symptom aggravation was significantly 
higher in patients experiencing an ILI (10/25, 40%) than in those with the common cold (15/96, 
15.6%, p=0.006).
Conclusions  The results of this study suggest that the potential risk of aggravating autoim-
mune disease is higher for ILI than for influenza vaccination, which further suggests that influ-
enza vaccination can be offered to patients with MG.
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The Impacts of Influenza Infection and Vaccination 
on Exacerbation of Myasthenia Gravis
INTRODUCTION
It is known that upper respiratory infections (URIs) can exacerbate the symptoms of my-
asthenia gravis (MG) and, in some cases, can precipitate a myasthenic crisis.1,2 Annual in-
fluenza vaccines are recommended by the Center for Disease Control (CDC) as the first 
and most important preventive step against influenza infection and the potentially seri-
ous complications it can cause for patients with chronic neurological disorders.3 However, 
there is concern that the vaccines themselves may trigger or worsen the symptoms of cer-
tain immune-system-related diseases. In particular, there have been recent reports of an 
association between influenza vaccination and the risk of developing immune-mediated 
diseases such as Guillain-Barre syndrome.4-7
Two previous studies that investigated the impact of influenza vaccination on patients 
with MG found no association between vaccination and patient safety, leading to the au-
Hung Youl Seoka,b*  
Ha Young Shinc*, Jong Kuk Kimd 
Byoung Joon Kime, Jeeyoung Ohf 
Bum Chun Suhg, Sun-Young Kimh 
Sa-Yoon Kangi, Suk-Won Ahnj 
Jong Seok Baek, Byung-Jo Kima
a Department of Neurology, Korea University 
Medical Center, Korea University College of 
Medicine, Seoul, Korea
b Department of Neurology, Keimyung 
University School of Medicine, Daegu, 
Korea
c Department of Neurology, Yonsei University 
College of Medicine, Seoul, Korea
d Department of Neurology, Dong-A  
University College of Medicine, Busan, 
Korea
e Department of Neurology, Samsung 
Medical Center, Sungkyunkwan University  
School of Medicine, Seoul, Korea
f Department of Neurology, Konkuk University 
School of Medicine, Seoul, Korea
g Department of Neurology, Kangbuk 
Samsung Hospital, Sungkyunkwan 
University School of Medicine, Seoul, Korea
h Department of Neurology, University of 
Ulsan College of Medicine, Ulsan, Korea
i Department of Neurology, Jeju National 
University School of Medicine, Jeju, Korea
j Department of Neurology, Chung-Ang 
University College of Medicine, Seoul, 
Korea
k Department of Neurology, Kangdong 
Sacred Hospital, Hallym University College 
of Medicine, Seoul, Korea
pISSN 1738-6586 / eISSN 2005-5013   /   J Clin Neurol 2017;13(4):325-330   /   https://doi.org/10.3988/jcn.2017.13.4.325
Received January 12, 2017
Revised February 26, 2017
Accepted February 28, 2017
Correspondence
Byung-Jo Kim, MD, PhD
Department of Neurology, Korea University 
Medical Center, Korea University College 
of Medicine, 73 Inchon-ro, Seongbuk-gu, 
Seoul 02841, Korea
Tel    +82-2-920-6619
Fax   +82-2-925-2472
E-mail    nukbj@korea.ac.kr
Byoung Joon Kim, MD, PhD
Department of Neurology, 
Samsung Medical Center, Sungkyunkwan 
University School of Medicine, 81 Irwon-ro, 
Gangnam-gu, Seoul 06351, Korea
Tel    +82-2-3410-2379
Fax   +82-2-3410-0423
E-mail    bjkim@skku.edu
*These authors contributed equally to this 
work.
cc  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Com-
mercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial 
use, distribution, and reproduction in any medium, provided the original work is properly cited.
JCN  Open Access ORIGINAL ARTICLE
326  J Clin Neurol 2017;13(4):325-330
Influenza Vaccination and Myasthenia GravisJCN
thors suggesting that seasonal influenza and H1N1 vaccines 
should be considered safe treatment options for MG pa-
tients.8,9 However, those studies focused mainly on the safety 
of influenza vaccination, and did not assess the risk of influ-
enza-infection-associated exacerbation of MG symptoms.
In the present study, we investigated the impact of both in-
fluenza vaccination and influenza infection on symptom se-
verity in MG patients.
METHODS
Subjects
Patients diagnosed with MG were consecutively enrolled 
from 10 university-affiliated hospitals across Korea between 
March and August 2015. The diagnosis of MG was based on 
clinical symptoms and a positive result in at least one of the 
following three laboratory diagnostic tests: neostigmine test, 
anti-acetylcholine receptor (AChR) antibody test, and repeti-
tive nerve stimulation test.10 We collected demographic and 
clinical data including age, gender, disease duration, labora-
tory findings, history of thymoma or thymectomy, and cur-
rent immunosuppressant regimen by reviewing the medical 
charts of all of the enrolled patients. All subjects were required 
to provide written informed consent, and the study was ap-
proved by the Institutional Review Board (IRB no. ED14307).
Influenza vaccination and influenza-like illness
In order to assess clinical information regarding the history 
of URI and seasonal influenza vaccination, we developed a 
recall-based questionnaire and administered it to all of the 
included subjects at their first routine follow-up visit during 
the study period. Subjects were asked about their URI histo-
ry–such as influenza-like illness (ILI) or the common cold–
during the previous winter. Additionally, the questionnaire 
asked specifically if and when the patients had received an 
influenza vaccination during the previous year. To differenti-
ate influenza-like symptoms after vaccination from actual 
influenza illness, questions regarding the dates of vaccine ad-
ministration and the onset of ILI were included in the ques-
tionnaire. Finally, the subjects were asked if they experienced 
any exacerbation of their MG symptoms following a URI or 
influenza vaccination event. To evaluate the severity of wors-
ening in MG symptoms, they were also asked to grade the 
degree of any exacerbation from 1 (representing “mildest pos-
sible exacerbation that did not interfere with daily activities”) 
to 10 (representing “worst possible exacerbation that required 
hospitalization”). MG symptom exacerbation was defined as 
an increase in the severity of at least one of the following ob-
jective symptoms: eyelid droop, double vision, difficulty hold-
ing the head up, facial muscle weakness affecting whistling 
or smiling, limb weakness, slurred or nasal speech, difficulty 
chewing or swallowing, or difficulty breathing. In accordance 
with the definition from the CDC, URIs were defined as 
symptoms related to URI that lasted for ≥1 day. ILI was differ-
entiated from the common cold by a fever of ≥38°C accompa-
nied by a cough and/or a sore throat.11 Patients with a URI but 
not an ILI were classified as having the common cold.
Statistical analyses
Subjects were grouped according to whether or not they had 
received an influenza vaccination during the previous year, 
and we compared their demographic and clinical variables for 
effects on MG symptom severity. These variables were also 
compared between the ILI group and the common-cold 
group of patients who had a URI. Differences in clinical data 
between groups were assessed using the Mann-Whitney or 
chi-square test. We performed a logistic regression analysis in 
order to detect factors influencing MG symptom severity. A p 
value of <0.05 was considered statistically significant. Statisti-
cal analyses were performed using SPSS version 21.0 (SPSS 
Inc., Chicago, IL, USA).
RESULTS
Clinical characteristics of the subjects
For this study, we enrolled a total of 258 patients [aged 54.1± 
15.2 years (mean±SD), 112 men, and 73 with ocular MG 
and 185 with generalized MG]. Positivity for the anti-AChR 
antibody was present in 220 (85.3%) of the subjects, and the 
median disease duration was 6.3 years (range=0.3–46.3 years). 
Of the 258 subjects, 184 (71.3%) had received prednisolone 
treatment and 117 (45.3%) had received other immunosup-
pressant drugs. In total, 111 subjects (43%) had undergone 
thymectomy, of which 32 were nonthymomatous MG cases, 
and the remaining 79 patients had thymoma. Overall, 133 
(51.6%) patients had received an influenza vaccination during 
the previous year, and 121 (46.9%) had experienced a com-
mon cold (96 patients) or ILI (25 patients) during the previ-
ous winter. There were no cases with influenza-like symptoms 
or signs within 30 days after vaccination. Table 1 presents 
the clinical characteristics of the patients with and without 
vaccination.
Comparison of clinical data between ILI and 
the common cold
There were no statistically significant differences in MG clin-
ical characteristics between the ILI and common-cold patient 
groups. However, the rate of MG symptom aggravation was 
significantly higher in ILI patients (10/25, 40.0%) than in the 
common-cold group (15/96, 15.6%, p=0.006), while the se-
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verity score for MG symptom aggravation did not differ sig-
nificantly between these two groups (Table 2). A stepwise 
multivariate logistic regression analysis showed that ILI sta-
tus was independently associated with MG exacerbation af-
ter adjusting for other confounding factors (odds ratio=3.20, 
95% confidence interval=1.15–8.92, p=0.026) (Table 3).
Impact of influenza infection versus influenza 
vaccination on MG symptom severity
MG symptom aggravation was found in 10 (40%) of 25 pa-
tients who had experienced an ILI during the previous winter, 
whereas only 2 of 133 patients (1.5% of 133) experienced 
symptom aggravation after receiving an influenza vaccina-
tion. The median severity score for symptom aggravation was 
7.5 (range=3–9) in the ILI group and 6.5 (range =3–10) in the 
vaccinated group. Symptom aggravation occurred within 1 
week after the ILI or influenza vaccination event in all cases.
DISCUSSION
We compared the impact of receiving a seasonal influenza 
vaccination or experiencing an influenza infection on symp-
tom severity among MG patients based on their responses to 
our self-report questionnaire. We found that the risk of MG 
symptom exacerbation following seasonal influenza vaccina-
tion was very low (1.5%, 2/133), while experiencing an ILI 
was significantly associated with exacerbation of MG symp-
toms (40%, 10/25).
Table 1. Demographic, clinical, and laboratory characteristics of the study subjects
All (n=258) Vaccinated (n=133) Unvaccinated (n=125) p
Age, years 54.1±15.2 60.0±13.6 47.8±14.4 <0.001
Gender, female 146 (56.6) 77 (57.9) 69 (55.2) 0.707
Disease duration, years 6.3 (0.3–46.3) 6.8 (0.3–46.3) 5.8 (0.3–45.0) 0.629
Generalized MG 185 (71.7) 94 (70.7) 91 (72.8) 0.782
Seropositivity for AChR antibody 220 (85.3) 114 (85.7) 106 (84.8) 0.862
Abnormal RNS test 188 (72.9) 93 (69.9) 95 (76.0) 0.317
Thymoma 80 (31.0) 42 (31.6) 38 (30.4) 0.787
Thymectomy for nonthymomatous MG 32 (12.4) 12 (9.0) 20 (16.0) 0.102
Prednisolone 184 (71.3) 91 (68.4) 93 (74.4) 0.335
Immunosuppressant 117 (45.3) 60 (45.1) 57 (45.6) 1.000
Prednisolone dosage, mg/day 5 (0–40) 5 (0–40) 7.5 (0–35) 0.260
URI 121 (46.9) 66 (49.6) 55 (44.0) 0.381
Common cold 96 (37.2) 55 (41.4) 41 (32.8) 0.265
Influenza-like illness 25 (9.7) 11 (8.3) 14 (11.2) 0.265
Data are mean±SD, n (%), or median (range) values.
AChR: acetylcholine receptor, MG: myasthenia gravis, RNS: repetitive nerve stimulation, URI: upper respiratory infection.
Table 2. Comparison of clinical data between the ILI and common-cold patient groups
ILI (n=25) Common cold (n=96) p
Age, years 53.0±16.3 55.2±15.2 0.411
Gender, female 19 (76.0) 59 (61.5) 0.242
Disease duration, years 6.0 (0.9–30.0) 6.7 (0.3–46.3) 0.389
Generalized MG 24 (96.0) 76 (79.2) 0.072
Seropositivity for AChR antibody 23 (92.0) 84 (87.5) 0.732
Abnormal RNS test 21 (84.0) 67 (69.8) 0.306
Thymoma 10 (40.0) 31 (32.3) 0.644
Thymectomy for nonthymomatous MG 3 (12.0) 13 (13.5) 0.769
Prednisolone 19 (76.0) 69 (71.9) 0.804
Immunosuppressant 13 (52.0)  41 (42.7) 0.499
Prednisolone dosage, mg/day 5 (0–30) 5 (0–40) 0.920
Vaccination  11 (44.0) 55 (57.3) 0.265
MG exacerbation 10 (40.0) 15 (15.6) 0.006
Severity score for MG symptom aggravation 7.5 (3–9) 6.0 (2–10) 0.251
Data are mean±SD, n (%), or median (range) values.
AChR: acetylcholine receptor, ILI: influenza-like illness, MG: myasthenia gravis, RNS: repetitive nerve stimulation.
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Previous studies have demonstrated that the influenza vac-
cine may sometimes trigger or exacerbate the symptoms of 
immune-mediated diseases such as Guillain-Barre syndrome, 
multiple sclerosis, and systemic lupus erythematosus.4-7 How-
ever, the impact of influenza vaccination on patients with 
MG has not been investigated thoroughly. To our knowledge, 
only two studies have assessed the safety of influenza vacci-
nation for MG patients.8,9 Those studies included 513 and 74 
MG patients and found no increased symptom risk follow-
ing seasonal or H1N1 influenza vaccination (although one of 
the studies did not consider mild symptom exacerbation in 
its assessment). Consistent with this previous work, we found 
that only 2 of the 133 patients (1.5%) who had received an in-
fluenza vaccination experienced exacerbation of MG symp-
toms. Together these results suggest that influenza vaccina-
tion is a safe option for MG patients.
In addition to assessing the safety of the influenza vaccine, 
the present study also determined the rate of influenza in-
fection-related MG symptom exacerbation; this is an im-
portant potential effect to assess since it needs to be included 
in decisions about whether or not MG patients should re-
ceive influenza vaccination. Although several previous stud-
ies have shown that MG patients have an increased risk of 
experiencing a myasthenic crisis following an infection,1,2 
there remains no evidence for a direct association between 
influenza infection and MG symptom severity. The present 
study conclusively found that ILI increased the probability of 
worsened MG symptoms (40% of patients, 10/25); this inci-
dence rate was 2.5-fold higher than in MG patients who ex-
perienced a common cold (15.6%, 15/96). Furthermore, our 
multivariate analysis revealed that ILI status was the only 
independent factor associated with MG exacerbation after 
adjusting for other confounding factors. These findings sug-
gest that influenza infection constitutes a specific and impor-
tant risk factor for MG symptom exacerbation. It is there-
fore important to apply preventive measures for influenza 
infection to MG patients, since it is one of only a few modi-
fiable risk factors for exacerbation of that disease.
Regarding vaccine efficacy, influenza vaccination did not 
confer protection for ILI since 11 (8.3%) of the 133 vaccinat-
ed patients had ILI compared with 14 (11.2%) of the unvacci-
nated patients. The reason for this suboptimal efficacy may 
be related to the vaccinated patients being older (60.0±13.6 
years) than the unvaccinated patients (47.8±14.4 years), since 
being older can lead to an increased risk of influenza infec-
tion and to insufficient protection after vaccination. Another 
possible reason for low vaccine efficacy is the failure of the 
influenza vaccine during 2014–2015. The effectiveness of the 
influenza vaccine was lower (23%) during that season in the 
United States than in previous seasons due to a poor match 
between the vaccine strain and the circulating influenza vi-
ruses.12 A study in Korea also did not demonstrate any sig-
nificant difference in the incidence of ILI between vaccinated 
and unvaccinated adults for the 2014–2015 season.13 There-
fore, our results do not necessarily mean that influenza vac-
cination is ineffective in patients with MG.
As noted above, in the present study 8.3% of vaccinated 
and 11.2% of unvaccinated patients were found to have suf-
fered from ILI. In Korea, 5–20% of the general population 
reportedly contract influenza each year,14 with the same inci-
dence range reported in the United States.15 The World Health 
Organization has estimated that the influenza virus infects 
Table 3. Results from univariate and multivariate analyses of MG symptom aggravation after URI
Variables
MG symptom aggravation after URI
Univariate Multivariate
OR (95% CI) p OR (95% CI) p
Age 0.99 (0.97–1.02) 0.663 0.99 (0.96–1.02) 0.612
Gender 0.38 (0.13–1.10) 0.074 0.43 (0.14–1.30) 0.135
Disease duration 0.99 (0.95–1.04) 0.721 1.00 (0.95–1.05) 0.895
Ocular or generalized MG 1.76 (0.47–6.53) 0.398 1.25 (0.31–4.97) 0.753
AChR antibody 0.88 (0.22–3.49) 0.860
RNS test 1.22 (0.41–3.65) 0.725
Thymoma 1.49 (0.58–3.79) 0.405
Thymectomy for nonthymomatous MG 2.05 (0.43–9.73) 0.365
Prednisolone 1.72 (0.59–5.05) 0.321
Immunosuppressant 1.50 (0.62–3.64) 0.370
Prednisolone dosage 1.04 (0.98–1.10) 0.208
Vaccination 1.35 (0.55–3.31) 0.516
ILI or common cold 3.76 (1.41–10.04) 0.008 3.20 (1.15–8.92) 0.026
AChR: acetylcholine receptor, CI: confidence interval, ILI: influenza-like illness, MG: myasthenia gravis, OR: odds ratio, RNS: repetitive nerve stimula-
tion, URI: upper respiratory infection.
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10–20% of the global population each year.16 A study in Ko-
rea that assessed the incidence rate for ILI during the 2014–
2015 season found that 11.3% of 265 adults had an ILI.13 
Therefore, compared to the general population, the rate of 
influenza in our MG patients was not high.
In this study, only 51.6% (133/258) of the MG patients had 
received seasonal influenza vaccination during the previous 
year (a rate that is similar to that in a previously reported 
study). A previous study found that MG patients who elected 
to not receive influenza vaccination cited reasons such as fear 
of general and nonmyasthenic side effects (42.6%), fear of 
MG exacerbation (31.5%), and advice from physicians to not 
receive vaccination (14.8%).9 Although the present study did 
not assess the reasons why subjects did not receive a vaccina-
tion, its results may help reassure MG patients and their phy-
sicians that the influenza vaccine does not increase the risk 
of symptom exacerbation. MG patients do not currently have 
adequate guidelines for being vaccinated against influenza. 
At present, the CDC limits its recommendation to live atten-
uated vaccines, which are contraindicated for patients with 
chronic neurological disorders and patients taking immuno-
suppressant medications due to their higher risk of severe 
complications.3,17 Our findings provide important informa-
tion for reassessing the guidelines relating to influenza vacci-
nation in patients with MG.
This study was subject to some potential limitations that 
should be considered when interpreting the findings. First, 
we analyzed a relatively small number of subjects. Second, 
because most of the analyzed information was collected us-
ing a recall-based self-report questionnaire, it is possible that 
our results were affected by reporting bias. Third, the true rate 
of MG symptom exacerbation was difficult to estimate due 
to the results being self-reported, and it may be that pseudo-
exacerbation events were inappropriately included. Fourth, 
influenza infection and vaccination may have different im-
pacts on patients with MG depending on the vaccine com-
ponents and the immunosuppressant status of each patient. 
Thus, similar to two previous studies,8,9 our study may have 
been biased by these potential confounding factors. In order 
to minimize the effect of vaccine components, unlike a pre-
vious study which included 14 influenza seasons,8 we restrict-
ed our study to a single influenza season; that is, 2014–2015. 
Of course, we could not determine commercial product types 
for the influenza vaccine for each participant because our 
study had a recall-based design. However, almost all of the 
influenza vaccines used in Korea are trivalent unadjuvanted 
inactivated vaccines,18 with quadrivalent influenza vaccines 
not being available in Korea during the 2014–2015 season. 
Therefore, although additional vaccine components such as 
preservatives, adjuvants, and trace compounds can vary slight-
ly between manufacturers, we assume that there are no dif-
ferences in the main active components of vaccines. Many of 
the MG patients received immunosuppressant treatments 
that may have altered their immune responses to a vaccine. 
To minimize the effects of these biases, we attempted to iden-
tify information about prednisolone and other immunosup-
pressive treatments for each participant, and these factors 
were adjusted for in our analysis (e.g., for the results present-
ed in Table 3). However, we did not examine the immuno-
suppressant status (e.g., dosage and duration) for all subjects, 
so our results are unlikely to be completely free from all po-
tential sources of bias.
In conclusion, we found no significant association between 
seasonal influenza vaccination and MG symptom severity. 
This supports previous findings that the influenza vaccine is 
safe for MG patients. Additionally, we noted that ILI is asso-
ciated with a substantially greater risk of symptom aggrava-
tion, and suggest that influenza vaccination should be rec-
ommended to MG patients as a preventive measure.
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